GoodRx (NASDAQ:GDRX) Shares Up 6.6% – Still a Buy?

GoodRx Holdings, Inc. (NASDAQ:GDRX)’s share price was up 6.6% during mid-day trading on Thursday . The company traded as high as $5.43 and last traded at $5.21. Approximately 406,469 shares traded hands during trading, a decline of 65% from the average daily volume of 1,148,701 shares. The stock had previously closed at $4.89.

Analysts Set New Price Targets

Several equities analysts have recently commented on GDRX shares. Wells Fargo & Company dropped their target price on shares of GoodRx from $9.00 to $8.00 and set an “overweight” rating for the company in a research report on Friday. Morgan Stanley cut their target price on GoodRx from $7.00 to $6.00 and set an “equal weight” rating for the company in a research note on Tuesday, December 17th. Citigroup decreased their price target on GoodRx from $7.00 to $6.25 and set a “buy” rating on the stock in a research note on Friday, January 10th. Mizuho began coverage on GoodRx in a research report on Wednesday, December 4th. They set a “neutral” rating and a $5.00 price objective for the company. Finally, Barclays decreased their target price on GoodRx from $10.00 to $6.00 and set an “overweight” rating on the stock in a research report on Monday, November 11th. Five analysts have rated the stock with a hold rating, seven have assigned a buy rating and one has assigned a strong buy rating to the stock. According to MarketBeat.com, GoodRx presently has a consensus rating of “Moderate Buy” and a consensus target price of $8.25.

GoodRx Stock Performance

The company has a current ratio of 5.48, a quick ratio of 5.48 and a debt-to-equity ratio of 0.70. The firm has a market capitalization of $1.90 billion, a price-to-earnings ratio of -166.00, a P/E/G ratio of 2.46 and a beta of 1.28. The firm’s 50-day moving average is $4.71 and its 200 day moving average is $5.74.

Hedge Funds Weigh In On GoodRx

A number of hedge funds have recently modified their holdings of the business. Vanguard Group Inc. raised its position in GoodRx by 5.8% during the 4th quarter. Vanguard Group Inc. now owns 8,373,039 shares of the company’s stock worth $38,935,000 after purchasing an additional 460,753 shares during the last quarter. Rubric Capital Management LP raised its position in shares of GoodRx by 25.2% during the third quarter. Rubric Capital Management LP now owns 4,680,028 shares of the company’s stock worth $32,479,000 after acquiring an additional 943,226 shares during the last quarter. Dimensional Fund Advisors LP lifted its stake in shares of GoodRx by 22.8% in the fourth quarter. Dimensional Fund Advisors LP now owns 1,992,311 shares of the company’s stock worth $9,264,000 after acquiring an additional 369,553 shares during the period. Point72 Asset Management L.P. bought a new stake in GoodRx in the third quarter valued at approximately $11,295,000. Finally, Clearbridge Investments LLC bought a new stake in GoodRx in the fourth quarter valued at approximately $5,863,000. Institutional investors and hedge funds own 63.77% of the company’s stock.

GoodRx Company Profile

GoodRx Holdings, Inc, together with its subsidiaries, offers information and tools that enable consumers to compare prices and save on their prescription drug purchases in the United States. The company operates a price comparison platform that provides consumers with curated, geographically relevant prescription pricing, and access to negotiated prices.